[{"orgOrder":0,"company":"Evoke Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Metoclopramide Hydrochloride","moa":"D2 receptor","graph1":"Gastroenterology","graph2":"Approved","graph3":"Evoke Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Evoke Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Evoke Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Evoke Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Metoclopramide Hydrochloride","moa":"D2 receptor","graph1":"Gastroenterology","graph2":"Approved","graph3":"Evoke Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Evoke Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Evoke Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Avenacy","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Metoclopramide Hydrochloride","moa":"","graph1":null,"graph2":null,"graph3":"Avenacy","amount2":0,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"amount2New":0,"dosageForm":"","sponsorNew":"Avenacy \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Avenacy \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals for Metoclopramide HCl

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          SupplySide West 2024
                          Not Confirmed
                          SupplySide West 2024
                          Not Confirmed

                          Details : Reglan-Generic (metoclopramide) is a 5-HT3a and D2 receptor inhibitor small molecule drug candidate indicated for the treatment of diabetic gastroparesis, & prevention of nausea and vomiting.

                          Brand Name : Reglan-Generic

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          September 16, 2024

                          Lead Product(s) : Metoclopramide Hydrochloride

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          SupplySide West 2024
                          Not Confirmed
                          SupplySide West 2024
                          Not Confirmed

                          Details : GIMOTI (metoclopramide) nasal spray, for relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults, has been added to Texas Medicaid PDL, supports reimbursement for GIMOTI on Texas Medicaid formulary and associated program.

                          Brand Name : Gimoti

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          April 19, 2022

                          Lead Product(s) : Metoclopramide Hydrochloride

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          SupplySide West 2024
                          Not Confirmed
                          SupplySide West 2024
                          Not Confirmed

                          Details : Gimoti is Evoke’s nasal spray product for the relief of symptoms in acute and recurrent diabetic gastroparesis. The patent covers methods of use for nasal delivery of metoclopramide for the treatment of gastroparesis.

                          Brand Name : Gimoti

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          June 02, 2021

                          Lead Product(s) : Metoclopramide Hydrochloride

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank